SMAD4 and cancer: Importantly, somatic mutations in key cancer genes such as KRAS, TP53, CDKN2A, and SMAD4 as well as a large number of genomic and epigenetic passenger alterations generate a remarkable inter- and intratumoural heterogeneity, which induces a considerable variation in responses to anticancer therapies [4].